Vivet presenting during the 1st Annual Optimizing AAV Safety Summit in Boston – Sept. 6-8, 2022
Vivet will be attending and presenting during the 1st Annual Optimizing AAV Safety Summit in Boston. With hundreds of clinical trials using AAV currently underway, it has never before been so important to create and implement an effective AAV safety strategy. Improving prediction of AAV toxicity, accurately monitoring potential safety signals, extracting safety data from non-clinical […]
Vivet attending 2nd Gene Patient Engagement congress in Boston – June 7-9, 2022
Vivet will be attending the 2nd Gene Patient Engagement congress with Sonia VALERO, Head of Clinical Operations and Patient Advocacy. On the agenda, very interesting sessions and roundtables are planned, notably: • Unique Characteristics of Gene Therapy & Their Ethical Implications For Clinical Trial Participation & Post-Approval Access • Setting & Managing Expectations of Gene […]
Vivet Therapeutics Announces 4 Presentations During the 2022 American Society Of Gene And Cell Therapy Annual Meeting
Vivet Therapeutics, a clinical-stage biotech company dedicated to developing gene therapy
Vivet presenting during 2022 ARM Meeting on the Med in Barcelona
Vivet Therapeutics BD Director, Thomas Daniel-Robin
VIVET ATTENDING 2021 WORLD ORPHAN DRUG CONGRESS EUROPE IN BARCELONA
Vivet Therapeutics CEO, Jean-Philippe Combal, will be participating to a panel during 2021 World Orphan Drug Congress Europe in Barcelona (Nov 15-18).
VIVET THERAPEUTICS ANNOUNCES 2 ORAL PRESENTATIONS AND 4 ABSTRACTS AT 2021 ESGCT ANNUAL MEETING
VIVET THERAPEUTICS ANNOUNCES 2 ORAL PRESENTATIONS AND 4 ABSTRACTS AT 2021 ESGCT ANNUAL MEETING
Vivet CDO, Anne Douar, presenting during SFTCG webinar on Gene Therapy for Wilson Disease
Vivet CDO, Anne Douar, will be presenting
Vivet Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 ASGCT Annual Meeting
Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting
VIVET ATTENDING ARM 2021 CELL & GENE MEETING ON THE MED
Jean-Philippe Combal, Vivet CEO, will be attending a panel during the Cell & Gene Meeting on the Med – virtual, organized by the ARM on April 6-9, 2021. The panel, “TRENDS AND CHALLENGES IN GENE THERAPY IN EUROPE”, will be held on April 7, 3-4pm CET.
VIVET ATTENDING JEFFERIES 2020 VIRTUAL LONDON HEALTHCARE CONFERENCE
Jean-Philippe Combal, Vivet Therapeutics’ CEO, and Thomas Daniel, BD Director, will be hosting 1×1 meetings during Jefferies 2020 London Healthcare Conference on November 17-19.